MarketCap
Facebook
X
Telegram
Inogen EBITDA | INGN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Inogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.55 M | -21.5 M | -91.2 M | -61.7 M | 30.9 M | 6.56 M | 33.6 M | 49.2 M | 39.9 M | 36.4 M | 29.1 M | 22.6 M | 13 M | 5.81 M | 1.48 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.2 M | -91.2 M | 5.63 M |
Quarterly EBITDA Inogen
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.5 M | -4.43 M | -3.18 M | -2.12 M | -2.47 M | - | -3.58 M | -2.91 M | -11 M | - | -42.3 M | -7.51 M | -17.8 M | - | -6.51 M | 822 K | -7.83 M | - | 22.2 M | 14.7 M | 2.97 M | - | 11.7 M | 6.59 M | 2.28 M | - | 17.3 M | 17.7 M | 7.65 M | - | 18.9 M | 19.8 M | 11.7 M | - | 17.6 M | 14.8 M | 8.78 M | - | 15.7 M | 14.9 M | 6.72 M | - | 14.2 M | 12.3 M | 5.96 M | - | 12.3 M | 9.55 M | 4.21 M | - | 6.88 M | 6.04 M | 2.29 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.2 M | -42.3 M | 4.86 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.74 | 6.75 % | $ 4.83 M |  USA |
 |
Smith & Nephew plc
SNN
|
1.37 B | $ 27.87 | 0.16 % | $ 24.2 B |  Britain |
 |
Stryker Corporation
SYK
|
6.46 B | $ 276.43 | 0.68 % | $ 106 B | USA |
 |
Tandem Diabetes Care
TNDM
|
26 M | $ 19.88 | 0.4 % | $ 1.35 B | USA |
 |
Sensus Healthcare
SRTS
|
-9.91 M | $ 3.16 | 0.94 % | $ 51.6 M | USA |
 |
Viemed Healthcare
VMD
|
51.6 M | $ 8.79 | 0.78 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
-4.6 M | $ 18.49 | 0.03 % | $ 765 M | USA |
 |
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | USA |
 |
Vivos Therapeutics
VVOS
|
-18.6 M | $ 0.18 | 6.76 % | $ 1.85 M | USA |
 |
TELA Bio
TELA
|
-33.1 M | $ 0.83 | 1.05 % | $ 39 M | USA |
 |
Beyond Air
XAIR
|
-25.9 M | $ 3.38 | 0.93 % | $ 28.1 B | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.19 B | $ 94.22 | 0.69 % | $ 18.7 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
25.2 M | $ 8.23 | 0.71 % | $ 600 M |  Israel |
 |
Axonics Modulation Technologies
AXNX
|
-13.6 M | - | - | $ 3.31 B | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Inari Medical
NARI
|
-7.14 M | - | - | $ 4.23 B | USA |
 |
Nemaura Medical
NMRD
|
-9.15 M | - | -17.8 % | $ 2.74 M | Britain |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
SmileDirectClub
SDC
|
-188 M | - | -53.45 % | $ 9.71 M | USA |
 |
Sientra
SIEN
|
-62.4 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-56.6 M | - | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
-76.3 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
169 M | - | - | $ 12.3 B | USA |
 |
ThermoGenesis Holdings
THMO
|
-7.46 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
-66 M | - | 3.55 % | $ 7.96 M | USA |
 |
Viveve Medical
VIVE
|
-20.4 M | - | -15.35 % | $ 1.71 M | USA |
 |
ViewRay
VRAY
|
-102 M | - | 1.54 % | $ 468 M | USA |
 |
Titan Medical
TMDI
|
-31 M | - | -26.32 % | $ 19.6 M | Canada |
 |
Natus Medical Incorporated
NTUS
|
51.9 M | - | 1.94 % | $ 1.05 B | USA |
 |
Acutus Medical
AFIB
|
240 K | - | -26.83 % | $ 2.62 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Profound Medical Corp.
PROF
|
-40.9 M | $ 6.81 | 1.32 % | $ 206 M | Canada |
 |
Tactile Systems Technology
TCMD
|
35.9 M | $ 21.73 | 0.09 % | $ 497 M | USA |
 |
Abbott Laboratories
ABT
|
9.49 B | $ 105.52 | 0.03 % | $ 184 B | USA |
 |
Aethlon Medical
AEMD
|
-6.97 M | $ 1.81 | 1.09 % | $ 1.22 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 6.19 | 1.09 % | $ 837 M | USA |
 |
Align Technology
ALGN
|
783 M | $ 153.49 | 0.03 % | $ 11.1 B | USA |
 |
Apyx Medical Corporation
APYX
|
-5.79 M | $ 3.05 | 0.33 % | $ 125 M | USA |
 |
Accuray Incorporated
ARAY
|
-18.5 M | $ 0.26 | 0.37 % | $ 31.9 M | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 9.19 | 1.29 % | $ 1.38 B | USA |
 |
AxoGen
AXGN
|
-1.19 M | $ 46.69 | 2.51 % | $ 2.15 B | USA |
 |
Butterfly Network
BFLY
|
-79.7 M | $ 7.52 | 2.17 % | $ 1.86 B | USA |